[go: up one dir, main page]

WO2022119230A1 - Composition antiallergique utilisant un extrait de persicaria longiseta - Google Patents

Composition antiallergique utilisant un extrait de persicaria longiseta Download PDF

Info

Publication number
WO2022119230A1
WO2022119230A1 PCT/KR2021/017458 KR2021017458W WO2022119230A1 WO 2022119230 A1 WO2022119230 A1 WO 2022119230A1 KR 2021017458 W KR2021017458 W KR 2021017458W WO 2022119230 A1 WO2022119230 A1 WO 2022119230A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
composition
extract
food
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/017458
Other languages
English (en)
Korean (ko)
Inventor
안은경
홍성수
조영락
박기태
이지은
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyeonggido Business And Science Accelerator
Original Assignee
Gyeonggido Business And Science Accelerator
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gyeonggido Business And Science Accelerator filed Critical Gyeonggido Business And Science Accelerator
Publication of WO2022119230A1 publication Critical patent/WO2022119230A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy

Definitions

  • the present invention relates to a composition for anti-allergy using an extract of Gaeyeogwi ( Persicaria longiseta ).
  • Allergy is a compound word created by combining the Greek words 'allos' meaning 'change' and 'ergo' meaning 'action'.
  • an allergy refers to a hypersensitivity reaction such as urticaria, itchiness, runny nose, and cough in a specific person due to an abnormality in innate or acquired immune function to an allergen, a substance that does not show any reaction to ordinary people.
  • Typical allergens include pollen, drugs, vegetable fibers, bacteria, mold, house dust mites, food (eg, egg albumin, milk protein, peanuts), hair dye, and chemicals. Due to an increase in substances, environmental pollution, a decrease in immune function due to stress, and changes in diet, these allergic diseases are increasing worldwide.
  • Allergic reactions are classified into five types: type I anaphylaxis type, type II cytolytic type, type III immune complex type, type IV cell mediated type, and type V stimulatory hypersensitivity type, most of which belong to type I, and generally Allergic reaction is used in the same sense as type I (Roitt I, Brostoff J, Male D. Immunology 6th eds. U.S.A. Mosby. 2001:323-383).
  • Suitable allergic diseases include atopic dermatitis, bronchial asthma, allergic rhinitis, allergic keratitis, and skin urticaria.
  • mast cells are known as important effector cells (Wills-Karp M., et al., Science, 282:2258-61, 1998; Grunig G., et al., Science, 282:2261-2263, 1998).
  • Mast cells are cells that are widely distributed in organs throughout the body, such as the skin, respiratory system, lymphatic vessels, mucous membranes of the gastrointestinal tract, blood vessels, and brain (Ishizaka t., et al. J. Immunol. 119:1589, 1997).
  • Allergic reactions are induced through activation of intracellular signaling pathways when an allergen binds to IgE, which is bound to the IgE high affinity receptor (Fc ⁇ RI) on the surface of mast cells.
  • IgE IgE high affinity receptor
  • T-helper cells and B cells are sequentially activated to generate IgE.
  • Allergens that invade the living body are recognized by antigen-presenting cells, which differentiate Th0 (T helper cell type 0) into Th2 cells by presenting the allergen.
  • the differentiated Th2 cells secrete cytokines such as IL-4, IL-5, and IL-13, which promote the development of acid leukocytes in the bone marrow and induce acid leukocytes to the inflamed tissue, as well as B cells. It induces the production of IgE and IgG1.
  • the generated IgE binds to the high-affinity IgE receptor (FcRI ⁇ ) of the mast cell membrane, and when allergens such as mites and pollen bind to it and cross-link it, the receptor (FcRI ⁇ ) aggregates.
  • FcRI ⁇ high-affinity IgE receptor
  • the increase in calcium ion concentration acts on several types of intracellular regulators such as cholesterol in the cell membrane and the cytoskeleton system, and moves the granules to the cell membrane, and at the same time degranulation through vacuolization of granules, fusion of granules with each other, and fusion of granules with cell membranes. causes When degranulation occurs, preformed mediators stored in mast cells, such as histamine, are released and, at the same time, newly synthesized prostaglandin and leukotriene are secreted together.
  • intracellular regulators such as cholesterol in the cell membrane and the cytoskeleton system
  • Chemical transmitters liberated by degranulation include histamine, serotonin, and leukotriene, which have actions such as vasodilation, enhancement of vascular permeability, contraction or hypersecretion of bronchial smooth muscle, and NCF acting as a chemotactic factor of inflammatory cells such as eosinophils and neutrophils. , ECF, PAF, etc.
  • Cyclooxygenase (COX) and lipoxygenase (LO) are known to catalyze a part of the process of producing prostaglandins and leukotrienes, which are allergy symptom-causing substances, from arachidonic acid (Sekiya K , et al., Biochem Biophys Acta 713:68-72, 1982)
  • substances that inhibit the activation of mast cells, inhibit the release of histamine, or inhibit the synthesis of prostaglandins and leukotrienes can be effective therapeutic drugs for allergies.
  • anti-allergic drugs include antihistamines (alkylamines, desloratadine, etc.), mast cell stabilizers (cromoglycate, etc.), leukotriene blockers (montelukast, etc.), and anti-IgE antibody (Omalizumab).
  • antihistamines alkylamines, desloratadine, etc.
  • mast cell stabilizers cromoglycate, etc.
  • leukotriene blockers montelukast, etc.
  • anti-IgE antibody Optab
  • the present invention discloses anti-allergic activity of the extract
  • the present invention inhibits degranulation when treated with the mast cell line RBL-2H3 (rat basophilic leukemia) activated with IgE and antigen (DNP-BSA). It is completed by doing
  • the present invention can be identified as an anti-allergy composition or antihistamine composition comprising the extract of Gaejaekyi as an active ingredient.
  • the term "gaeyeogwi extract” refers to the stem, leaf, fruit, flower, root, outpost, above-ground part, underground part, or a mixture thereof, which is an extraction target, water, a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, butanol, etc.) ), methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or It refers to an extract obtained by leaching using a mixed solvent, an extract obtained by using a supercritical extraction solvent such as carbon dioxide or pentane, or a fraction obtained by fractionating the extract, and the extraction method is the polarity of the active material, extraction degree, and preservation degree In consideration of this, any method such as chilling, reflux, warming, ultrasonic radiation,
  • the meaning of the extract includes a concentrated liquid extract or solid extract from which the extraction solvent is removed by methods such as freeze drying, vacuum drying, hot air drying, spray drying, and the like.
  • it refers to an extract obtained by using water, ethanol, or a mixed solvent thereof as an extraction solvent, and more preferably an extract obtained by using a mixed solvent of water and ethanol as an extraction solvent.
  • active ingredient refers to a component that alone exhibits the desired activity or can exhibit activity together with a carrier that has no activity by itself.
  • anti-allergy is meant to include improvement (relief of symptoms), treatment, and prevention (suppression or delay of onset) of allergic diseases as defined below.
  • allergic disease means a pathological symptom caused by an allergic reaction mediated by the activation of mast cells, such as degranulation of mast cells, and such allergic diseases include atopic dermatitis, asthma. , allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, allergic keratitis, and the like.
  • the anti-allergic composition of the present invention may contain the active ingredient in any amount (effective amount) as long as it can exhibit the amelioration activity of the intended treatment according to the use, formulation, purpose of formulation, etc. It will be determined within the range of 0.001% to 15% by weight based on the total weight of the composition.
  • the term "effective amount” refers to the intended medical and pharmacological effects, such as the improvement of allergic diseases, when the composition of the present invention is administered to a mammal, preferably a human subject to the application, during the administration period as suggested by a medical professional. It refers to the amount of the active ingredient included in the composition of the present invention. Such an effective amount can be determined empirically within the ordinary ability of one of ordinary skill in the art.
  • the anti-allergic composition of the present invention may further include any compound or natural extract known to have anti-allergic activity and safety has already been verified to increase/reinforce anti-allergic activity.
  • Enterococcus faecalis heat-treated dry powder which has been individually recognized for its 'alleviation of hypersensitivity immune response' function according to the ⁇ Health Functional Food Act ⁇ in Korea
  • a complex such as guava leaf extract, Actinidia extract, leaf extract, Composite such as picaopreto powder, PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol), L. sakei Probio 65, which has been individually recognized for its 'improving sensitive skin condition' function, oil containing gamma-linolenic acid , fruit and vegetable-derived lactic acid bacteria ( L. plantarum CJLP133 ), probiotics ATP, and the like.
  • One or more of these compounds or natural extracts may be included in the anti-allergic composition of the present invention together with its active ingredient.
  • the anti-allergic composition of the present invention can be grasped as a food composition.
  • the composition of the present invention is identified as a food composition, its use may be understood to inhibit allergic skin hypersensitivity reaction.
  • the food composition of the present invention can be prepared in any form, for example, beverages such as tea, juice, carbonated drinks, and ion drinks, processed oils such as milk and yogurt, gums, rice cakes, Korean sweets, bread, confectionery, noodles, etc. Foods, tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, and health functional food preparations such as bars can be manufactured.
  • beverages such as tea, juice, carbonated drinks, and ion drinks
  • processed oils such as milk and yogurt, gums, rice cakes, Korean sweets, bread, confectionery, noodles, etc.
  • Foods, tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, and health functional food preparations such as bars can be manufactured.
  • the food composition of the present invention may have any product classification in terms of legal and functional classification as long as it conforms to the enforcement laws at the time of manufacture and distribution.
  • it is a health functional food according to Korea's "Health Functional Food Act”, or confectionery, beans, tea, and beverages according to each food type in the Food Ordinance of Korea “Food Sanitation Act” (Ministry of Food and Drug Safety Notification “Food Standards and Specifications”) , special purpose food, and the like.
  • the food composition of the present invention may contain food additives in addition to the active ingredients thereof.
  • Food additives can be generally understood as substances that are mixed or infiltrated with food in manufacturing, processing, or preserving food. Food additives with guaranteed safety are limited in terms of ingredients or functions in the Food Additives Ordinance in accordance with the laws of each country that regulates the manufacture and distribution of food (“Food Sanitation Act” in Korea). In the Korean Food Additives Code (“Food Additive Standards and Specifications” notified by the Ministry of Food and Drug Safety), food additives are classified into chemically synthetic products, natural additives, and mixed preparations in terms of ingredients. It is classified into an agent, a preservative, an emulsifier, an acidulant, and a thickener.
  • the sweetener is used to impart appropriate sweetness to food, and both natural and synthetic ones may be used in the composition of the present invention.
  • a natural sweetener is used.
  • sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.
  • Flavoring agents may be used to improve taste or aroma, and both natural and synthetic ones may be used. Preferably, it is a case where a natural thing is used. In the case of using a natural product, the purpose of nutritional enhancement in addition to flavor may be concurrently used.
  • the natural flavoring agent may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, or the like, or obtained from green tea leaves, honeysuckle, bamboo leaves, cinnamon, chrysanthemum leaves, jasmine, and the like. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, and ginkgo can be used.
  • the natural flavoring agent may be a liquid concentrate or a solid extract.
  • a synthetic flavoring agent may be used, and the synthetic flavoring agent may be an ester, an alcohol, an aldehyde, a terpene, or the like.
  • sodium calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. can be used, and as an emulsifier, acacia gum, carboxymethylcellulose, xanthan gum, Pectin, etc. are mentioned, and acidulant, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, etc. can be used as an acidulant.
  • the acidulant may be added so that the food composition has an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing the taste.
  • a thickening agent As a thickening agent, a suspending agent, a settling agent, a gel former, a bulking agent, etc. can be used.
  • the food composition of the present invention may contain, in addition to the food additives described above, physiologically active substances or minerals known in the art for the purpose of supplementing and reinforcing functionality and nutrition and guaranteed stability as food additives.
  • physiologically active substances include catechins contained in green tea and the like, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoylthiamine, and the like.
  • Minerals include calcium preparations such as calcium citrate, magnesium stearate
  • Magnesium preparations, such as iron preparations, such as iron citrate, chromium chloride, potassium iodide, selenium, germanium, vanadium, zinc, etc. are mentioned.
  • the food additives as described above may be included in an appropriate amount to achieve the purpose of the addition according to the product type.
  • composition of the present invention may be regarded as a pharmaceutical composition in another specific embodiment.
  • the pharmaceutical composition of the present invention may be prepared as an oral dosage form or a parenteral dosage form according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient.
  • the route of administration may be any suitable route including topical route, oral route, intravenous route, intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination.
  • An example of the combination of two or more routes is a case in which two or more formulations of drugs according to the route of administration are combined. For example, one drug is first administered by an intravenous route and the other drug is secondarily administered by a local route.
  • Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or formulation, and specifically, reference may be made to the pharmacopoeia of each country including the "Korea Pharmacopoeia”.
  • suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Cellulose such as hydroxypropylmethylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, glycerol and the like.
  • suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Cellulose such as hydroxypropylmethylcellulose, polyvinylpyr
  • an appropriate binder, lubricant, disintegrant, colorant, diluent, etc. may be included as needed.
  • Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweetener, sodium alginate, polyethylene glycol, wax, and the like, and lubricants include sodium oleate.
  • the disintegrant includes starch, methyl cellulose, agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt and the like.
  • the diluent include lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine.
  • the pharmaceutical composition of the present invention When the pharmaceutical composition of the present invention is prepared for parenteral use, it may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories together with suitable carriers according to methods known in the art.
  • suitable carriers for aqueous isotonic solution or suspension
  • PBS phosphate buffered saline
  • isotonic solution such as 5% dextrose
  • formulated for transdermal administration When formulated for transdermal administration, it can be formulated in the form of an ointment, a cream, a lotion, a gel, an external solution, a pasta agent, a liniment agent, an air roll, and the like.
  • a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, and the like.
  • tween 61 polyethylene glycols, cacao fat, laurin fat, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters, and the like can be used.
  • a preferred dosage of the pharmaceutical composition of the present invention is in the range of 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 1 g, depending on the patient's condition, weight, sex, age, severity of the patient, and the route of administration. It can be in the range /kg. Administration may be performed once or divided into several times a day. These dosages should not be construed as limiting the scope of the invention in any respect.
  • the composition of the present invention can be identified as a cosmetic composition.
  • a cosmetic composition its use may be understood as a use for suppressing allergic skin troubles, alleviating allergic skin irritation, and the like.
  • the cosmetic composition can be classified into any product in terms of its use or by law, and specifically functional cosmetics, non-functional products having uses such as improvement of skin troubles and improvement of atopic dermatitis It may be general cosmetics and the like.
  • product form it may take any product form, and specifically, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax It can take the form of products such as foundation and spray.
  • it may be in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.
  • the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the active ingredient, for example, conventional adjuvants such as stabilizers, solubilizers, surfactants, vitamins, pigments and fragrances, and carriers.
  • conventional adjuvants such as stabilizers, solubilizers, surfactants, vitamins, pigments and fragrances, and carriers.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • a solvent, solubilizer or emulsifier is used as a carrier component, specifically water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, etc. may be used.
  • the formulation of the present invention is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, polyoxyethylene sorbitan ester, microcrystals
  • cellulose aluminum metahydroxide, bentonite, agar, etc.
  • the formulation of the present invention is a surfactant-containing cleansing agent
  • Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like may be used.
  • the cosmetic composition of the present invention can be prepared according to the method for preparing a cosmetic composition conventionally performed in the art, except that it contains the active ingredient exhibiting anti-allergic activity.
  • composition for anti-allergy of the present invention may be commercialized as food, cosmetics, drugs, etc. for the purpose of improving allergic diseases.
  • FIG. 1 is a result showing the degranulation inhibitory activity in the mast cell line RBL-2H3 (rat basophilic leukemia) activated with IgE and antigen (DNP-BSA) of Gaeyeogwi extract.
  • Rat basophilic leukemia cell line RBL-2H3 cell line, in MEM medium containing 15% FBS, 100 unit/ml penicillin and streptomycin and 2 ⁇ 10 5 /well in a 24 well plate at 37°C and 5% CO 2 condition. After dispensing, culture was performed for 24 hours.
  • MEM medium containing 25 ng/ml anti-DNP IgE was added and cultured for 4 hours. After incubation, the cells were washed twice with PIPES buffer (25mM PIPES, 119mM NaCl, 5mM KCl, 1mM CaCl 2 , 0.4mM MgCl 2 , 40mM NaOH, 5.6mM glucose, 0.1% BSA) and pre-incubated for 10 minutes. After pre-incubation, the samples of Example were treated for 20 minutes by concentration and then reacted with DNP-BSA for 20 minutes.
  • PIPES buffer 25mM PIPES, 119mM NaCl, 5mM KCl, 1mM CaCl 2 , 0.4mM MgCl 2 , 40mM NaOH, 5.6mM glucose, 0.1% BSA
  • Ketotifen used as a positive control, is an antihistamine, which is used for allergic skin diseases such as allergic rhinitis, atopic dermatitis, and allergic asthma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition antiallergique utilisant un extrait de Persicaria longiseta, l'extrait présentant une activité de suppression de la dégranulation lorsqu'il est utilisé sur la leucémie à basophiles de rat (RB-2H3) qui est une lignée cellulaire de l'obésité activée par les IgE et un antigène (DNP-BSA).
PCT/KR2021/017458 2020-12-01 2021-11-25 Composition antiallergique utilisant un extrait de persicaria longiseta Ceased WO2022119230A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0166024 2020-12-01
KR1020200166024A KR102529778B1 (ko) 2020-12-01 2020-12-01 개여뀌 추출물을 이용한 항알러지용 조성물

Publications (1)

Publication Number Publication Date
WO2022119230A1 true WO2022119230A1 (fr) 2022-06-09

Family

ID=81854154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/017458 Ceased WO2022119230A1 (fr) 2020-12-01 2021-11-25 Composition antiallergique utilisant un extrait de persicaria longiseta

Country Status (2)

Country Link
KR (1) KR102529778B1 (fr)
WO (1) WO2022119230A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102624448B1 (ko) * 2023-01-05 2024-01-12 조문창 버섯균사체 곡립 종균을 이용한 기능성 발효 인삼씨앗 추출물의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100874114B1 (ko) * 2007-05-31 2008-12-15 주식회사 코리아나화장품 개여뀌 추출물을 유효성분으로 함유하는 화장료 조성물
KR101049041B1 (ko) * 2011-04-08 2011-07-13 강원대학교산학협력단 항염증 및 면역억제 효과를 갖는 여뀌 메탄올 추출물
KR101224238B1 (ko) * 2010-09-27 2013-01-18 정의수 혼합 식물 추출물
JP2016150914A (ja) * 2015-02-17 2016-08-22 学校法人福岡大学 アトピー性皮膚炎の予防治療用組成物、並びに当該予防治療用組成物を配合してなる医薬組成物、化粧料組成物及び機能性食品

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100874114B1 (ko) * 2007-05-31 2008-12-15 주식회사 코리아나화장품 개여뀌 추출물을 유효성분으로 함유하는 화장료 조성물
KR101224238B1 (ko) * 2010-09-27 2013-01-18 정의수 혼합 식물 추출물
KR101049041B1 (ko) * 2011-04-08 2011-07-13 강원대학교산학협력단 항염증 및 면역억제 효과를 갖는 여뀌 메탄올 추출물
JP2016150914A (ja) * 2015-02-17 2016-08-22 学校法人福岡大学 アトピー性皮膚炎の予防治療用組成物、並びに当該予防治療用組成物を配合してなる医薬組成物、化粧料組成物及び機能性食品

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
.: "Gyeonggi-do. 6 Cases of Natural Functional Ingredients such as 'Persicaria Longiseta Extract' Listed in the International Cosmetic Ingredient Book", COSINKOREA.COM, COSINKOREA.COM, KOREA, 2 July 2021 (2021-07-02), Korea, pages 1 - 2, XP055936638, Retrieved from the Internet <URL:https://cosinkorea.com/mobile/article.html?no=39765> [retrieved on 20220629] *
HOSSEN MUHAMMAD JAHANGIR, KIM SEUNG CHEOL, SON YOUNG-JIN, BAEK KWANG-SOO, KIM EUNJI, YANG WOO SEOK, JEONG DEOK, PARK JAE GWANG, KI: "AP-1-Targeting Anti-Inflammatory Activity of the Methanolic Extract of Persicaria chinensis", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, OXFORD UNIVERSITY PRESS, US, vol. 2015, 1 January 2015 (2015-01-01), US , pages 1 - 11, XP055936631, ISSN: 1741-427X, DOI: 10.1155/2015/608126 *
HUQ A. K. M. MOYEENUL, JAMAL JAMIA AZDINA, STANSLAS JOHNSON: "Ethnobotanical, Phytochemical, Pharmacological, and Toxicological Aspects of Persicaria hydropiper (L.) Delarbre", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, OXFORD UNIVERSITY PRESS, US, vol. 2014, 1 January 2014 (2014-01-01), US , pages 1 - 11, XP055936627, ISSN: 1741-427X, DOI: 10.1155/2014/782830 *
JEONG SIM, GWAK CHUN DUG, KIM: "Persicaria thunbergii Extract as a Physiologically Active Cosmetic Ingr edient", ASIAN JOURNAL OF BEAUTY AND COSMETOLOGY, vol. 16, no. 3, 22 August 2018 (2018-08-22), pages 381 - 392, XP055936624, ISSN: 2466-2046 *

Also Published As

Publication number Publication date
KR102529778B1 (ko) 2023-05-09
KR20220076984A (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
KR101816742B1 (ko) 감태 추출물과 괭생이모자반 추출물을 이용한 항알레르기 조성물
KR20240087883A (ko) 검정말 추출물을 이용한 피부 염증 반응 억제용 조성물
KR102351363B1 (ko) 수용화 매스틱 검 또는 감태나무 추출물을 이용한 항알러지용 조성물
KR101946121B1 (ko) 꽃송이버섯 추출물로부터 분리된 5-하이드록시-6,7-디메톡시프탈라이드를 이용한 항알러지용 조성물과 아토피 피부염 개선용 조성물
WO2022119230A1 (fr) Composition antiallergique utilisant un extrait de persicaria longiseta
KR102119421B1 (ko) 개오동나무 추출물을 이용한 항알러지용 조성물
KR20220076982A (ko) 누리장나무 추출물을 이용한 항알러지용 조성물
KR102357619B1 (ko) 연꽃 추출물 또는 예덕나무 추출물을 이용한 항염증, 항알러지용 또는 항산화용 조성물
KR20190036974A (ko) 며느리배꼽 추출물을 이용한 항염증 및 항알러지 조성물
KR102885032B1 (ko) 까치박달 추출물을 이용한 항알러지용 조성물
KR101855823B1 (ko) 글리코스미스 펜타필라 추출물을 이용한 항알러지용 조성물
KR102760576B1 (ko) 대추나무 잎 추출물을 이용한 항알러지용 조성물
KR102369909B1 (ko) 범꼬리 추출물을 이용한 항알러지용 조성물
KR102040527B1 (ko) 람노시트린을 이용한 항염증용 조성물
KR102497941B1 (ko) 넓은잎외잎쑥 추출물을 이용한 항염증 조성물과 항알러지 조성물
KR102171987B1 (ko) 나도하수오 추출물을 이용한 항알러지 개선용 조성물
KR101845639B1 (ko) 정향풀 추출물을 이용한 항알러지용 조성물
KR20240112687A (ko) 골담초 추출물을 이용한 항알러지용 조성물
KR102048977B1 (ko) 유근피 추출물 및 자소엽 추출물을 이용한 항알러지용 조성물
KR102114674B1 (ko) 네튬 마크로스타키움 추출물을 이용한 항알러지용 조성물
KR101787266B1 (ko) 디프테로카푸스 인트리카투스 추출물을 이용한 항알러지용 조성물
KR102040528B1 (ko) 신규 퀴놀론 유도체 및 이를 이용한 항알러지용 조성물
KR101972076B1 (ko) 카레야 아르보레아 추출물에서 분리한 활성성분을 이용한 아토피 피부염 개선용 조성물
KR20190060631A (ko) 감태 추출물과 괭생이모자반 추출물을 이용한 아토피 피부염 개선용 조성물
KR101857350B1 (ko) 신규 미리세틴 유도체 및 이를 이용한 항염증용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21900918

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21900918

Country of ref document: EP

Kind code of ref document: A1